Study to evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults with Moderate to Severe Acne

About this study

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of an Acne mRNA vaccine in adults between 18 to 45 years with moderate to severe acne.

The study hopes to determine whether this vaccine is safe, effective and will produce an immune response against the development of acne.

  • ClinicalTrials.gov Identifier: NCT06316297
  • Sanofi Reference No: VBE00001
  • HREC Reference Number: HREC/116806/Alfred-2025

Who is eligible to participate?

  • Between 18 and 45 years with moderate to severe facial acne vulgaris
  • No prior use of tretinoin
  • Can not have active nodulocystic acne and/or secondary acne (eg. Chloracne, drug-induced acne)

Please note, other eligibility criteria may apply.

What’s involved?

  • Attending the Alfred Hospital at monthly intervals over 8–10 months
  • Having 2 –3 intramuscular injections of placebo or mRNA vaccine
  • Completing questionnaires and skin exams
  • Safety blood tests

To find out more:

Contact the Alfred Dermatology trials’ study coordinator: E: dermtrials@alfred.org.au | T: 03 9076 8592